Abstract
Neuroleptic drug-induced acute extrapyramidal syndromes are one of the major reasons why patients discontinue their antipsychotic medicines. The typical (e.g., haloperidol) neuroleptic drug produces acute extrapyramidal symptoms in the majority of patients, whereas the atypical (clozapine) neuroleptic produces only minimal motor system side effects. Serotonin S2 antagonists often reduce or prevent catalepsy in rodents, but the limited number of studies in nonhuman primates have produced conflicting results. The hypothesis of a high serotonin S2/dopamine D2 antagonism ratio as a mechanism underlying atypical neuroleptic effects in preventing acute extrapyramidal syndromes deserves further evaluation in nonhuman primate models because extrapyramidal symptoms in monkeys closely resemble those in patients. Cebus monkeys (22–28 years old) were tested with compounds that ranged from low to high S2/D2 antagonism ratios. These were haloperidol, fluphenazine, clopenthixol, melperone, tefludazine, setoperone, risperidone, and clozapine. A saline control was included with a wide dose range of each of these drugs that was tested in a once-weekly, blindly-scored random drug administration schedule. Dystonia was scored on four different symptoms by an experienced rater who was blind to drug dosage. All the compounds, with the exception of clozapine, produced clinically indistinguishable dose-related dystonia. The only difference was the dose at which dystonia appeared. In contrast to rodent studies, these nonhuman primate investigations with drugs, spanning a wide range of S2/D2 antagonism ratios, produced clinically similar extrapyramidal symptoms. Thus, adding an S2 antagonism component to neuroleptics does not appear to provide an explanation for the motor side effect profile of atypical neuroleptics, or a method for designing neuroleptic drugs that will be free of extrapyramidal symptoms.
Similar content being viewed by others
References
Arnt J, Hyttel J, Bach-Lauritsen T (1986) Further studies of the mechanism behind scopolamine-induced reversal of antistereotypic and cataleptogenic effects of neuroleptics in rats. Acta Pharmacol Toxicol 59:319–324
Balsara JJ, Jadhav JH, Chandorkar AG (1979) Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology 62:67–69
Bjerkenstedt L, Härnryd C, Grimm V, Gullberg B (1978) A double-blind comparison of melperone and thiothixene in psychotic women using a new rating scale, the CPRS. Arch Psychiatr Nervenkr 226:157–172
Borison RL, Diamond BI, Pathiraja A, Meibach RC (1992) Clinical overview of risperidone. In: Meltzer HY (ed) Novel antipsychotic drugs. Raven Press, New York, pp 233–239
Casey DE (1989a) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99:S47-S53
Casey DE (1989b) Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates. Psychopharmacol Bull 25[3]:457–459
Casey DE (1991a) Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 4:109–120
Casey DE (1991b) Extrapyramidal syndromes in nonhuman primates: typical and atypical neuroleptics. Psychopharmacol Bull 27[1]:47–50
Casey DE (1992) What makes a neuroleptic atypical? In: Meltzer HY (ed) Novel antipsychotic drugs. Raven Press, New York, pp 241–251
Casey DE, Keepers GA (1988) Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. In: Casey DE, Christensen AV (eds) Psychopharmacology: current trends. Springer, Berlin Heidelberg New York, pp 74–93
Casey DE, Gerlach J, Christensson E (1980) Dopamine, acetylcholine, and GABA effects in acute dystonia in primates. Psychopharmacology 70:83–87
Ceulemans DLS, Gelders YG, Hoppenbrouwers M-LJA, Reyntjens AJM, Janssen PAJ (1985) Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology 85:329–332
Coward DM, Imperato A, Urwyler S, White TG (1989) Biochemical and behavioural properties of clozapine. Psychopharmacology 99:S6-S12
Deniker P (1984) Introduction of neuroleptic chemotherapy into psychiatry. In: Ayd FJ, Blackwell B (eds) Discoveries in biological psychiatry. Ayd, Baltimore, pp 155–164
Farde L, Wiesel FA, Nordström AL, Sedvall G (1989) D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99:S28-S31
Gerlach J, Casey DE (1990) Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys. Prog Neuropsychopharmacol Biol Psychiatry 14:103–112
Hall H, Sällemark M, Jerning E (1986) Effects of remoxipride and some related new substituted salicylamides on rat brain receptors. Acta Pharmacol Toxicol 58:61–70
Hyttel J, Larsen JJ, Christensen AV and Arnt J (1985) Receptor-binding profiles of neuroleptics. In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia: research and treatment. Springer, Berlin Heidelberg New York, pp 9–18
Kane J, Honigfield G, Singer J, Meltzer HY (1988) Clorazil collaborative study group: clozapine in the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/benztropine. Arch Gen Psychiatry 45:789–796
Keepers GA, Clappison VJ, Casey DE (1983) Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 40:1113–1117
Korsgaard S, Gerlach J, Christensson E (1985) Behavioral aspects of serotonin-dopamine interaction in the monkey. Eur J Pharmacol 118:245–252
Lewander T, Westerbergh S-E, Morrison D (1990) Clinical profile of remoxipride — a combined analysis of a comparative double-blind multicentre trial programme. Acta Psychiatr Scand 82 [Suppl.358]:92–98
Leysen JE, Gommeren W, Janssen PFM, Van Gompel P, Janssen PAJ (1988a) Receptor interactions of dopamine and serotonin antagonists: binding in vitro and in vivo and receptor regulation. In: Casey DE, Christensen AV (eds) Psychopharmacology: current trends. Springer, Berlin Heidelberg New York, pp 12–26
Leysen JE, Gommeren W, Eens A, deChaffoy de Courcelles D, Stoof JC, Janssen PAJ (1988b) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661–670
Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin pKi values. J Pharmacol Exp Ther 251:238–246
Niemegeers CJE, Leysen JE, Laduron PM, Janssen PAJ (1984) Proc 14th CINP Congress, Abstract 667
Povlsen UJ, Noring U, Laursen AL, Korsgaard S, Gerlach J (1986) Effects of serotonergic and anticholinergic drugs in haloperidol-induced dystonia in cebus monkeys. Clin Neuropharmacol 9:84–90
Svendsen O, Arnt J, Boeck J, Bogeso KP, Christensen AV, Hyttel J, Larsen J-J (1986) The neuropharmacological profile of tefludazine, a potential antipsychotic drug with dopamine and serotonin receptor antagonistic effects. Drug Dev Res 7:35–47
Waldmeier PC, Delini-Stula AA (1979) Serotonin-dopamine interactions in the nigrostriatal system. Eur J Pharmacol 55:363–373
Ögren SO, Hall H, Köhler C, Magnusson O, Lindblom L-O, Ängeby K, Florvall L (1984) Remoxipride, a new potential antipsychotic compound with selective anti-dopaminergic actions in the rat brain. Eur J Pharmacol 102:459–474
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Casey, D.E. Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology 112 (Suppl 1), S55–S59 (1993). https://doi.org/10.1007/BF02245007
Issue Date:
DOI: https://doi.org/10.1007/BF02245007